share_log

Privia Health Group Analyst Ratings

Privia Health Group Analyst Ratings

Privia 健康集团分析师评级
Benzinga Analyst Ratings ·  2023/02/03 06:27
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
02/03/2023 15.52% Goldman Sachs → $32 Initiates Coverage On → Buy
12/09/2022 1.08% Stifel → $28 Initiates Coverage On → Buy
12/08/2022 8.3% UBS → $30 Initiates Coverage On → Buy
11/11/2022 55.23% Canaccord Genuity $50 → $43 Maintains Buy
11/11/2022 40.79% SVB Leerink $46 → $39 Maintains Outperform
09/07/2022 94.95% Truist Securities $48 → $54 Assumes → Buy
08/25/2022 80.51% Canaccord Genuity $45 → $50 Maintains Buy
08/12/2022 73.29% Truist Securities $40 → $48 Maintains Buy
08/12/2022 84.12% Guggenheim $36 → $51 Maintains Buy
08/12/2022 48.01% Credit Suisse $33 → $41 Maintains Outperform
08/12/2022 58.84% Cowen & Co. $35 → $44 Maintains Outperform
08/12/2022 66.06% SVB Leerink $33 → $46 Maintains Outperform
07/14/2022 44.4% Truist Securities $36 → $40 Maintains Buy
05/13/2022 4.69% Canaccord Genuity $44 → $29 Maintains Buy
05/13/2022 19.13% Credit Suisse $43 → $33 Maintains Outperform
05/13/2022 19.13% SVB Leerink $44 → $33 Maintains Outperform
05/03/2022 -2.53% B of A Securities → $27 Initiates Coverage On → Buy
04/28/2022 26.35% BTIG → $35 Initiates Coverage On → Buy
03/30/2022 26.35% Guggenheim → $35 Initiates Coverage On → Buy
03/25/2022 58.84% SVB Leerink $43 → $44 Maintains Outperform
03/24/2022 58.84% Canaccord Genuity $50 → $44 Maintains Buy
02/22/2022 26.35% Cowen & Co. → $35 Upgrades Market Perform → Outperform
01/03/2022 19.13% Jefferies → $33 Initiates Coverage On → Buy
12/08/2021 55.23% SVB Leerink $42 → $43 Maintains Outperform
11/09/2021 51.62% SVB Leerink $35 → $42 Maintains Outperform
09/27/2021 26.35% SVB Leerink → $35 Initiates Coverage On → Outperform
09/10/2021 11.91% Cowen & Co. → $31 Initiates Coverage On → Market Perform
06/30/2021 105.78% Credit Suisse $44 → $57 Maintains Outperform
05/24/2021 44.4% JP Morgan → $40 Initiates Coverage On → Overweight
05/24/2021 44.4% Piper Sandler → $40 Initiates Coverage On → Overweight
05/24/2021 58.84% Credit Suisse → $44 Initiates Coverage On → Outperform
05/24/2021 44.4% Truist Securities → $40 Initiates Coverage On → Buy
05/24/2021 69.68% Canaccord Genuity → $47 Initiates Coverage On → Buy
05/24/2021 — William Blair Initiates Coverage On → Outperform
日期 上行/下行 分析公司 目标价格变化 评级变化 上一次/当前评级
02/03/2023 15.52% 高盛 → $32 开始承保 →购买
12/09/2022 1.08% Stifel → $28 开始承保 →购买
12/08/2022 8.3% 瑞银集团 → $30 开始承保 →购买
11/11/2022 55.23% 卡纳科特·格纳奇 $50 → $43 维护 买
11/11/2022 40.79% SVB Leerink $46 → $39 维护 跑赢大盘
09/07/2022 94.95% Truist证券 $48 → $54 假设 →购买
08/25/2022 80.51% 卡纳科特·格纳奇 $45 → $50 维护 买
08/12/2022 73.29% Truist证券 $40 → $48 维护 买
08/12/2022 84.12% 古根海姆 $36 → $51 维护 买
08/12/2022 48.01% 瑞士信贷 $33 → $41 维护 跑赢大盘
08/12/2022 58.84% 考恩公司 $35 → $44 维护 跑赢大盘
08/12/2022 66.06% SVB Leerink $33 → $46 维护 跑赢大盘
07/14/2022 44.4% Truist证券 $36 → $40 维护 买
05/13/2022 4.69% 卡纳科特·格纳奇 $44 → $29 维护 买
05/13/2022 19.13% 瑞士信贷 $43 → $33 维护 跑赢大盘
05/13/2022 19.13% SVB Leerink $44 → $33 维护 跑赢大盘
05/03/2022 -2.53% B of A证券 → $27 开始承保 →购买
04/28/2022 26.35% BTIG → $35 开始承保 →购买
03/30/2022 26.35% 古根海姆 → $35 开始承保 →购买
03/25/2022 58.84% SVB Leerink $43 → $44 维护 跑赢大盘
03/24/2022 58.84% 卡纳科特·格纳奇 $50 → $44 维护 买
02/22/2022 26.35% 考恩公司 → $35 升级 市场表现优于→
01/03/2022 19.13% 杰富瑞 → $33 开始承保 →购买
12/08/2021 55.23% SVB Leerink $42 → $43 维护 跑赢大盘
11/09/2021 51.62% SVB Leerink $35 → $42 维护 跑赢大盘
09/27/2021 26.35% SVB Leerink → $35 开始承保 →跑赢大盘
09/10/2021 11.91% 考恩公司 → $31 开始承保 →市场表现
06/30/2021 105.78% 瑞士信贷 $44 → $57 维护 跑赢大盘
05/24/2021 44.4% 摩根大通 → $40 开始承保 →超重
05/24/2021 44.4% 派珀·桑德勒 → $40 开始承保 →超重
05/24/2021 58.84% 瑞士信贷 → $44 开始承保 →跑赢大盘
05/24/2021 44.4% Truist证券 → $40 开始承保 →购买
05/24/2021 69.68% 卡纳科特·格纳奇 → $47 开始承保 →购买
05/24/2021 — 威廉·布莱尔 开始承保 →跑赢大盘

What is the target price for Privia Health Group (PRVA)?

Privia Health Group(PRVA)的目标价格是多少？

The latest price target for Privia Health Group (NASDAQ: PRVA) was reported by Goldman Sachs on February 3, 2023. The analyst firm set a price target for $32.00 expecting PRVA to rise to within 12 months (a possible 15.52% upside). 22 analyst firms have reported ratings in the last year.

高盛于2023年2月3日报道了Privia Health Group(纳斯达克：PRVA)的最新目标价。这家分析公司将目标价定为32.00美元，预计Prva将在12个月内上涨至15.52%。过去一年，有22家分析公司公布了评级。

What is the most recent analyst rating for Privia Health Group (PRVA)?

Privia Health Group(PRVA)的最新分析师评级是什么？

The latest analyst rating for Privia Health Group (NASDAQ: PRVA) was provided by Goldman Sachs, and Privia Health Group initiated their buy rating.

普瑞维亚健康集团(纳斯达克：PRVA)的最新分析师评级由高盛提供，普瑞维亚健康集团启动了他们的买入评级。

When is the next analyst rating going to be posted or updated for Privia Health Group (PRVA)?

Privia Health Group(PRVA)的下一次分析师评级将于何时发布或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Privia Health Group, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Privia Health Group was filed on February 3, 2023 so you should expect the next rating to be made available sometime around February 3, 2024.

分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Privia Health Group的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Privia Health Group的上一次评级是在2023年2月3日提交的，因此您应该预计下一次评级将在2024年2月3日左右提供。

Is the Analyst Rating Privia Health Group (PRVA) correct?

分析师对Privia Health Group(PRVA)的评级正确吗？

While ratings are subjective and will change, the latest Privia Health Group (PRVA) rating was a initiated with a price target of $0.00 to $32.00. The current price Privia Health Group (PRVA) is trading at is $27.70, which is within the analyst's predicted range.

虽然评级是主观的，并将发生变化，但Privia Health Group(PRVA)的最新评级是以0.00美元至32.00美元的目标价启动的。Privia Health Group(PRVA)目前的股价为27.70美元，在分析师的预测范围内。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发